GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sichuan Kelun Pharmaceutical Co 002422.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

44.25

-1.84%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥18.51bn

FY2016FY2025

Net income

CN¥1.70bn

FY2016FY2025

Free cash flow

CN¥1.02bn

FY2016FY2025

Shareholders' equity

CN¥24.22bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥18.51bnCN¥21.81bnCN¥21.45bnCN¥19.04bnCN¥17.28bnCN¥16.46bnCN¥17.64bnCN¥16.35bnCN¥11.43bnCN¥8.57bn
Gross profitCN¥8.86bnCN¥11.20bnCN¥11.16bnCN¥9.95bnCN¥9.28bnCN¥8.60bnCN¥10.57bnCN¥9.67bnCN¥5.79bnCN¥3.63bn
Research and developmentCN¥2.21bnCN¥2.17bnCN¥1.94bnCN¥1.80bnCN¥1.74bnCN¥1.53bnCN¥1.29bnCN¥908.6mCN¥712.2mCN¥547.4m
Operating incomeCN¥2.49bnCN¥4.43bnCN¥3.65bnCN¥2.20bnCN¥1.32bnCN¥1.22bnCN¥1.28bnCN¥1.36bnCN¥1.16bnCN¥972.6m
Net incomeCN¥1.70bnCN¥2.94bnCN¥2.46bnCN¥1.71bnCN¥1.10bnCN¥829.4mCN¥937.9mCN¥1.21bnCN¥748.5mCN¥584.6m
Diluted earnings per share1.071.831.591.140.760.580.660.830.520.42

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥39.83bnCN¥37.32bnCN¥36.45bnCN¥34.21bnCN¥31.54bnCN¥32.01bnCN¥31.49bnCN¥29.34bnCN¥27.99bnCN¥23.41bn
Cash and short-term investments—CN¥5.90bnCN¥6.37bnCN¥5.18bnCN¥3.28bnCN¥3.04bnCN¥2.25bnCN¥2.03bnCN¥1.74bnCN¥1.35bn
Total liabilitiesCN¥10.54bnCN¥10.58bnCN¥13.44bnCN¥17.33bnCN¥17.41bnCN¥18.01bnCN¥17.58bnCN¥16.40bnCN¥16.01bnCN¥11.94bn
Debt—CN¥4.20bnCN¥7.13bnCN¥10.31bnCN¥11.84bnCN¥12.50bnCN¥11.63bnCN¥11.13bnCN¥11.40bnCN¥9.48bn
Shareholders' equityCN¥24.22bnCN¥22.48bnCN¥19.67bnCN¥15.73bnCN¥13.86bnCN¥13.50bnCN¥13.19bnCN¥12.75bnCN¥11.80bnCN¥11.33bn
Shares outstanding1,598m1,602m1,540m1,493m1,457m1,422m1,431m1,467m1,448m1,376m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥2.64bnCN¥4.49bnCN¥5.34bnCN¥3.13bnCN¥2.85bnCN¥2.22bnCN¥2.22bnCN¥2.95bnCN¥1.20bnCN¥1.73bn
Capital spending−CN¥1.62bn−CN¥1.68bn−CN¥1.77bn−CN¥896.0m−CN¥990.6m−CN¥1.23bn−CN¥1.33bn−CN¥1.33bn−CN¥1.48bn−CN¥1.37bn
Free cash flowCN¥1.02bnCN¥2.81bnCN¥3.57bnCN¥2.23bnCN¥1.86bnCN¥988.5mCN¥885.7mCN¥1.62bn−CN¥274.0mCN¥355.9m
Dividends paid−CN¥1.09bn−CN¥1.81bn−CN¥1.13bn−CN¥597.8m−CN¥450.0m−CN¥602.2m−CN¥300.1m−CN¥983.9m−CN¥647.1m−CN¥716.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥4.58bnCN¥4.26bnCN¥5.24bnCN¥4.19bnCN¥4.69bnCN¥4.39bnCN¥5.02bnCN¥4.96bn
Gross profitCN¥2.27bnCN¥1.93bnCN¥2.50bnCN¥1.84bnCN¥2.32bnCN¥2.14bnCN¥2.38bnCN¥2.47bn
Operating incomeCN¥577.5mCN¥310.7mCN¥764.4mCN¥154.3mCN¥719.7mCN¥793.7mCN¥616.3mCN¥898.0m
Net incomeCN¥674.1mCN¥453.7mCN¥501.3mCN¥200.0mCN¥416.4mCN¥584.2mCN¥465.0mCN¥670.8m
Diluted earnings per share0.420.280.310.130.260.370.290.42
Cash from operations———CN¥537.0mCN¥740.0mCN¥449.0mCN¥1.22bnCN¥742.0m
Capital spending−CN¥262.0m−CN¥412.0m−CN¥462.0m−CN¥393.0m−CN¥353.0m−CN¥412.0m−CN¥395.0m−CN¥374.0m
Free cash flow———CN¥144.0mCN¥387.0mCN¥37.0mCN¥822.0mCN¥368.0m
Total assetsCN¥41.49bnCN¥41.14bnCN¥39.83bnCN¥40.10bnCN¥39.05bnCN¥37.83bnCN¥37.32bnCN¥38.39bn
Cash and short-term investments———CN¥7.84bnCN¥7.06bnCN¥6.32bnCN¥5.90bnCN¥7.08bn
DebtCN¥183.8mCN¥191.1mCN¥191.1mCN¥3.59bnCN¥3.37bnCN¥3.28bnCN¥2.80bnCN¥3.48bn
Shareholders' equityCN¥24.62bnCN¥24.64bnCN¥24.22bnCN¥23.71bnCN¥23.68bnCN¥23.09bnCN¥22.48bnCN¥22.56bn

Financial ratios

Data as of 17 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin47.8%51.3%52.0%52.3%53.7%52.2%
Operating margin13.4%20.3%17.0%11.5%7.6%7.4%
Net margin9.2%13.5%11.4%9.0%6.4%5.0%
Return on equity7.0%13.1%12.5%10.8%8.0%6.1%
Return on assets4.3%7.9%6.7%5.0%3.5%2.6%
Free cash flow yield6.7%9.6%11.5%6.7%6.6%6.1%
Revenue growth-15.1%1.7%12.7%10.2%4.9%-6.6%
Earnings growth-42.0%19.5%44.0%54.7%32.9%-11.6%
Current ratio2.18x1.96x1.83x1.38x1.04x1.20x
Debt to equity0.01x0.12x0.31x0.51x0.50x0.69x
Equity ratio60.8%60.2%54.0%46.0%43.9%42.2%
Interest coverage24.20x28.62x9.86x4.55x2.48x2.12x
R&D as a share of sales11.9%10.0%9.1%9.4%10.1%9.3%
Buybacks as a share of market value0.2%-4.0%-3.1%-2.5%-2.5%0.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-0.9%2.4%9.1%
Operating income4.3%15.3%15.8%
Net income-0.1%15.5%10.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin49.7%50.9%51.6%52.1%
Operating margin17.1%15.8%13.4%11.7%
Net margin11.5%10.9%9.4%8.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings27.616.318.223.325.033.335.825.048.238.0
Price to sales2.52.22.12.11.61.71.91.93.12.6

Dividends and splits

Per share, in the currency the company pays

Paid for 15 years. Last went ex-dividend on 11 May 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.4680.6291.060.6160.4260.3190.4250.21
  • 2-for-1 split · 22 Jul 2015
  • 3-for-2 split · 1 Jul 2014
  • 2-for-1 split · 29 Apr 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.